Main Article Content
Varicella is the most contagious viral exanthematous disease, which has a variable clinical course. We studied a seroepiderniologicaJ study on varicella antibody in 350 healthy children at Department of Child Health, Medical School, University of Indonesia, Dr. Cipto Mangunkusumo Hospital, Jakarta; from May to July 1998. The aim of this study was to get figures of varicella antibody in healthy chiJdren which can be used as a baseline data in the decision of recommendation in varicella vaccination. Subjects were 1-12 years old children with no history of varicella infection or immunization. The varicella antibody was determined by using Etisa assay (Enzygnost lest). Among 350 healthy children, 42.9% were males; they were divided into 3 age groups: 1-3, 4-7 and 8-12 years. Fourty two children (11.1 %) had seropositive varicella antibody (above protective level 0.2 mIU/ml). The prevalence of subclinical valicella significance increased with increasing age. Subjects with clinical or subclinical varicella had the same figure of age specific prevalence. The mean varicella antibody in each age group was almost similar. The minimum varicella antibody titer was quite similar between 1-3 and 4-7 age group, but not in 8-12 age group. Forty one percent had history of varicella contact, older chiildren had more history of contact.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
2. Preblud SR, Orenstein WA, Bart KJ. Varicella: clinical manifestations, epidemiology and health impact in children. Pediatr Infect Dis J. 1984;3:505-9.
3. Chao PW, Dohnahue JG, Manson JE. The epidemiology of varicella complications. J Infect Dis 1995; 172:706-12.
4. Plotkin SA, Arbetter, Starr SE. The future of varicella vaecine. Postgr Med J. 1985; 61:155-62.
5. Huse OM, Meissner HD, Lacey MJ, Oster G. Childhood vaecination against chickenpox: an analysis of benefits and costs. J Pediatr 1994;124;869-74.
6. Lee BW. Clinical experience in Asia with a live attenuated varicella vaccine. Seminar on Vaccine today-protecting the future. Kuala Lumpur, Malaysia, March 18-19. 1998.
7. Graham R. Varicella serology in 4-9 years old children in Jogyakarta. Presented in Seminar on variceua vaccine. IDAI Jaya, Jakarta October 10.1997.
8. Hadinegoro SR. Varisela pada anal<. Presented in Pertemuan ilmiah: Varisela pada anak. IDI Ciamis, July 9.1997.
9. Budiardja SA, SUgito TL. Epidemiology of varicella and preliminary reports on acyclovir treatment in varicella patienta. Presented in the 8th RCD, Pattaya, Thailand, May 11-14.1996.
10. Lieu TA, Black SB, Takahashi H, et.al. Variceua serology among school age children with a negative or uncertain history of chickenpox. Pediatr Infect Dis J. 1998;17:120-5.
11. Hadinegom SR. Pedoman pelaksanaan imunisasi pada anak. Naskah lengkap PKB llmu Kesehatan Anak XXXIX. Balai Penerbit FKUI, Jakarta 1997:37-49.
12. Commitee on Infectious Diseases American Academy of Pediatrics. Recommendations for use of live attenuated varicella vaecine. Pediatrics 1995;95:791-6.